CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 366 enrolled
Drug / intervention
Tradipitant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04327661
NCT04327661Phase 3Completed
CompareCT.gov

Motion Syros: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness During Travel

Vanda Pharmaceuticals·interventional·Posted Mar 31, 2020·Updated Dec 11, 2024

In Brief

A Phase 3 clinical trial evaluating Tradipitant and Placebo for Motion Sickness. Completed, enrolled 366 participants across 7 sites.

Detailed Summary

A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in subjects affected by motion sickness during travel

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMotion Sickness
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedMar 31, 2020
Enrollment StartNov 15, 2021
Primary CompletionApr 1, 2023
Study CompletionApr 12, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.3 years ago

Interventions

Tradipitantdrug

Oral Capsule

Placebodrug

Oral Capsule